Clinical Report: Prognostic and Clinical Significance of PTTG1 in Solid Tumors
Overview
This meta-analysis evaluates the prognostic significance of PTTG1 expression in solid tumors, revealing that high levels correlate with poorer overall and disease-free survival.
Background
PTTG1 is an oncogene implicated in cancer pathogenesis, influencing tumor cell proliferation and metastasis. Understanding its role in prognosis is crucial for developing targeted therapies.
Data Highlights
Outcome
Hazard Ratio (HR)
95% Confidence Interval (CI)
Overall Survival
1.85
1.55-2.20
Disease-Free/Recurrence-Free Survival
3.48
1.81-6.70
Key Findings
High PTTG1 expression is associated with poorer overall survival (HR: 1.85).
High PTTG1 expression correlates with worse disease-free survival (HR: 3.48).
Subgroup analysis indicates significant associations in renal cell carcinoma, non-small cell lung cancer, breast cancer, esophageal squamous cell carcinoma, and laryngeal cancer.
High PTTG1 expression is linked to advanced tumor stage (III-IV vs I-II).
PTTG1 expression is significantly associated with lymphatic invasion and metastasis.
Clinical Implications
Further research may be warranted to explore the clinical significance of PTTG1 expression in various cancers.
Conclusion
PTTG1 expression serves as a significant prognostic indicator in various solid tumors.
